Research programme: botulism vaccines - DynPort Vaccine Company

Drug Profile

Research programme: botulism vaccines - DynPort Vaccine Company

Latest Information Update: 03 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
  • Developer Cambridge Biostability; DynPort Vaccine Company
  • Class
  • Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Botulism

Most Recent Events

  • 03 Apr 2008 Preclinical development of a vaccine against seven botulinum neurotoxins is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top